Thu, Dec 25, 2014, 9:35 PM EST - U.S. Markets closed for Christmas

Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

robert.vince 91 posts  |  Last Activity: Dec 11, 2014 7:42 PM Member since: Aug 30, 2012
  • Swiss researchers have suspended the testing of one of the leading Ebola vaccine candidates after some volunteers reported unexpected side effects. In a statement issued on Thursday, the Hopitaux Universitaires de Geneve said the trial had been suspended "as a precautionary measure." The study involving 59 people began in November. The vaccine was developed by the Canadian government and is licensed to two U.S. companies, NewLink and Merck The trial is scheduled to resume in January in Geneva.

  • robert.vince robert.vince Dec 11, 2014 12:16 PM Flag

    Me too, I sold in the $20's, sadly my mom still has it.

  • Reply to

    Science matters

    by duestscience Dec 5, 2014 12:53 PM
    robert.vince robert.vince Dec 7, 2014 10:30 AM Flag

    Pleasure to have you on this board good sir!

  • Reply to

    Science matters

    by duestscience Dec 5, 2014 12:53 PM
    robert.vince robert.vince Dec 7, 2014 10:28 AM Flag

    Pay no attention the the jcturdle behind the curtain

  • robert.vince robert.vince Dec 5, 2014 10:13 AM Flag

    Dr. Phillip Chan, CEO of CytoSorbents Corporation, stated, "This agreement marks our first expansion into Eastern Europe and we are pleased to be working with Smart Medical Solutions. They have a proven track record of commercializing blood purification technologies in the intensive care unit, and have a well-established key opinion leader network that can be leveraged when marketing CytoSorb®. We look forward to an outstanding collaboration."

    Mr. Stefan Baudis, International Sales Director of CytoSorbents Europe who now manages worldwide distribution, stated, "Smart Medical Solutions has very successfully completed our initial evaluation phase. Already during this period, they have substantially contributed to the development of our business in these new countries and I am looking forward to working with them as an anchor of growth in this part of Europe."

    CytoSorb® is the only specifically approved extracorporeal cytokine adsorber approved for sale in all 28 countries of the European Union and in countries that accept CE Mark approval. Now marketed in a total of 21 countries, CytoSorb® is sold directly in Germany, Austria and Switzerland, with expanding distribution in the United Kingdom, Ireland, the Netherlands, Turkey, India, Russia, Taiwan, Kingdom of Saudi Arabia, United Arab Emirates, Bahrain, Kuwait, Qatar, Yemen, Iraq, Jordan and Oman, and now Romania and Moldova.

  • CytoSorbents Corporation (CTSO), a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to treat critically-ill patients in multiple countries worldwide, announced an exclusive agreement with Smart Medical Solutions S.R.L., to distribute CytoSorb® for critical care applications in Romania and the neighboring Republic of Moldova. This multi-year agreement is subject to annual minimum guaranteed orders of CytoSorb® to maintain exclusivity.
    Romania has 20 million inhabitants and is the seventh most populous country in the European Union. It is classified as an upper-middle income country that provides universal healthcare to its citizens. There are 425 operational hospitals across the country, of which approximately 130 are private hospitals or clinics that are generally paid for by private insurance. Romania is a leader in solid organ transplantation in the E.U., with one of the highest surgical success rates in the European Union. CytoSorb® has now been used successfully multiple times in Romania in this complex patient population.

    Mr. Dan Popescu, CEO of Smart Medical Solutions, stated, "In this early phase of our relationship we already have experienced amazing therapeutic results by applying CytoSorb® Therapy to patients who suffered from extremely life-threatening critical illnesses. We are proud to have demonstrated our ability to work with Romanian thought leaders in this field and foresee an impressive development of the therapy as a whole."

  • robert.vince robert.vince Dec 5, 2014 7:18 AM Flag

    Also explains yesterdays drop most likely. AF must leak his articles prior to releasing them to the public. Shaking out the folks trying to make a quick buck while giving investors another great opportunity to pick up shares on the cheap. I said it before, the only pump Aethlon needs is the dialysis machine.

    Sentiment: Strong Buy

  • Reply to

    Have you baggies noticed....

    by booogaluu Dec 4, 2014 10:35 AM
    robert.vince robert.vince Dec 4, 2014 10:54 AM Flag

    The only pump Aethlon needs is the Dialysis machine. Its only the day traders and quick money seekers that are getting burned right now, the horizon is clearly bright for this company.

    Sentiment: Strong Buy

  • robert.vince robert.vince Dec 4, 2014 10:50 AM Flag

    If thats the truth, credit probably doesn't matter, they'll pay in cash. ;)

  • robert.vince robert.vince Dec 2, 2014 9:16 PM Flag

    I emailed Adam a bunch of times when this was .10 a share asking for his opinion, ignored my requests, now its 5 times the price (just the beginning) and he decides to trash it? I've given up on him.

  • Reply to

    Oh come on!!

    by minnguy64 Dec 2, 2014 3:12 PM
    robert.vince robert.vince Dec 2, 2014 3:48 PM Flag

    You my clueless friend, are a moron, and not a nice one either.

  • robert.vince by robert.vince Dec 2, 2014 7:46 AM Flag

    Aethlon further disclosed that it established an elution protocol during the study that allowed researchers to quantify the number of viruses captured within the Hemopurifier® during a single treatment. As a result, researchers were able the measure that as many as 300 billion copies of HCV had been captured during a single six-hour treatment.

  • robert.vince robert.vince Dec 2, 2014 7:42 AM Flag

    Data from two patients was not included in the reported Hemopurifier-PR dataset. One of these patients was a genotype-5 patient who discontinued PR therapy at day 180, yet still achieved a SVR. The second patient was a genotype-3 patient who also achieved a SVR, yet was unable to tolerate PR therapy and discontinued therapy at day-90. Overall, ten of the twelve patients (n=10/12) who enrolled in the study achieved a SVR and seven of the twelve (n=7/12) patients achieved an RVR.

    Aethlon further disclosed that it established an elution protocol during the study that allowed researchers to quantify the number of viruses captured within the Hemopurifier® during a single treatment. As a result, researchers were able the measure that as many as 300 billion copies of HCV had been captured during a single six-hour treatment.

    Aethlon is now preparing to launch the first U.S. clinical Hemopurifier® based on the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study, which will be conducted at the DaVita MedCenter Dialysis in Houston, Texas, will contribute safety data to support the advancement of Hemopurifier® therapy as a broad-spectrum countermeasure against bioterror and pandemic threats and chronic viral pathogens such as HIV and HCV. Hemopurifier® therapy is available to treat Ebola patients in the U.S. through FDA expanded access "emergency use" provisions to address life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans.

  • robert.vince robert.vince Dec 2, 2014 7:40 AM Flag

    In the study, HCV-infected individuals were enrolled to receive three six-hour Hemopurifier® treatments during the first three days of a 48-week peginterferon+ribavirin (PR) treatment regimen. The study was conducted under the leadership of Dr. Vijay Kher at the Medanta Medicity, a multi-specialty medical institute established to be a premier center for medical tourism in India. Aethlon reported that Hemopurifier® therapy was well tolerated and without device-related adverse events in twelve treated patients. Of these twelve patients, ten completed the Hemopurifier-PR treatment protocol, including eight genotype-1 patients and two genotype-3 patients. Eight of the ten patients (n=8/10) achieved a sustained virologic response (SVR), which is the clinical definition of treatment cure and is defined as undetectable HCV RNA 24-weeks after the completion of the 48-week PR drug regimen. Both genotype-3 patients achieved a SVR (n=2/2), while six of the eight genotype-1 patients achieved a SVR (n=6/8)

    Of the ten patients that completed the full treatment protocol, five (n=5/10) also achieved a rapid virologic response (RVR), defined as undetectable HCV RNA at day 30 of therapy. RVR represents the clinical endpoint that best predicts SVR cure rates resulting from PR therapy. As a point of reference, the landmark IDEAL Study of 3,070 HCV genotype-1 patients documented that 10.35% (n=318/3070) of PR treated patients achieved a RVR. Patients that achieved a RVR had SVR rates of 86.2% (n=274/318) versus SVR rates of 32.5% (n=897/2752) in non-RVR patients. Aethlon also disclosed that two of the genotype-1 patients who achieved a RVR also achieved an immediate virologic response (IVR), defined as undetectable HCV RNA seven days after initiation of Hemopurifier-PR treatment protocol. The incidence of IVR was not reported in the IDEAL study.

  • Aethlon Medical, Inc. (AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, today reported final clinical outcomes, including rapid virologic response (RVR) and sustained virologic response (SVR) rates, in Hepatitis-C virus (HCV) infected individuals who received Hemopurifier® therapy during a clinical study conducted at the Medanta Medicity Institute in India. Aethlon is now preparing to launch its first human clinical studies in the United States.
    The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. The device is a leading broad-spectrum treatment countermeasure against viral pathogens that are not treatable with drug or vaccine therapies. In HCV care, the device is positioned to address antiviral drug resistance and hard-to-treat patients who are unable to tolerate normally administered doses of antiviral drugs or peginterferon+ribavirin (PR) therapy. It is estimated that approximately 170 million people worldwide are infected with HCV, which leads to chronic liver disease or cirrhosis, and is a leading cause of liver transplantation.

    In addition to reporting RVR and SVR rates, Aethlon disclosed that it achieved the following clinical objectives of the HCV study:

    To demonstrate that Hemopurifier® therapy could be administered safely in non-dialysis patients who were infected with HCV.
    To demonstrate the ability to combine Hemopurifier® therapy with an established therapeutic drug regimen.
    To demonstrate that the brief inclusion of Hemopurifier® therapy can improve the normally expected benefit of a therapeutic drug regimen.
    To establish an elution protocol that allows researchers to quantify the number of viruses captured within the Hemopurifier® during a single treatment.

    Sentiment: Strong Buy

  • Green PolkaDot Box Incorporated (GPDB) "GPDB" or "Company" announced today that Registrations for the new Health Merchant program began on November 25th . In spite of the late start...along with the fact that Health Merchant stores will not go live until later this month, the Company signed up 29 Health Merchants over the Thanksgiving Holiday weekend.

    20 of the 29 Health Merchants enrolled on the Company's FAST TRACT plan. The FAST TRACK plan requires a commitment of $1,995, plus $100 monthly for the life of the Health Merchant's store and it includes a lifetime buyout of the Media Kit and Promotions subscription. The remaining nine activated on the Standard plan, paying $300 for their store, plus $100 monthly.

    After years of development and millions of dollars expended by Green PolkaDot Box...independent health professionals and entrepreneurs will have the opportunity to own a self-branded, replication of its website. The Company's intention is to help and support Health Merchants in building their own customer groups by providing them with proven marketing tools.

    Health Merchant Plan

    The GPDB Health Merchant Program is intended for a health care practitioners, including doctors who have medical practices oriented to prevention of disease, nutritionists, chiropractors, homeopaths that each have thousands of patients who want to eat healthy, save money and enjoy the convenience of home delivery. Other potential Health Merchants will include entrepreneurs who are interested in capitalizing on the expanding marketplace for organic and non-GMO foods, along with health store owners who don't have an online presence, gym owners, personal fitness trainers, health coaches, pharmacists and many others.

    Sentiment: Strong Buy

  • Reply to

    Sierra : conservatively $1 to 5 soon...

    by olddog1122 Nov 30, 2014 5:18 AM
    robert.vince robert.vince Nov 30, 2014 11:29 AM Flag

    Scam site or not, I do like this line from their recommendation:
    Here is why Sierra’s publisher has initiated a long position in AEMD, the last 6 weeks have provided positive scientific data and successful human results that are nothing short of miraculous. There is little doubt that shares of Aethlon Medical (AEMD) will soon be trading conservatively in the $1 to $5 range!

  • robert.vince robert.vince Nov 29, 2014 4:00 PM Flag

    I think this article is showing that it hasn't slowed down, just looks like the media isn't covering it like they started to.

  • robert.vince robert.vince Nov 29, 2014 3:45 PM Flag

    Not sure how many dialysis machines they have in Africa. They plug the hemopurifier into the machine to do its work.

  • Death toll from virus outbreak nears 7,000 as World Health Organisation warns figures may be significant underestimation.
    The number of people with Ebola in west Africa has risen above 16,000, with the death toll from the outbreak reaching almost 7,000, the World Health Organisation (WHO) says.

    The number of deaths is more than 1,000 higher than the figure issued by the WHO just two days ago, but it is thought to include deaths that have gone unreported in the weeks or months since the outbreak began. Most of the new deaths were recorded in Liberia.

    The WHO has warned that its figures could be a significant underestimation of the number of infections and deaths. Data from the outbreak has been patchy and the totals often rise considerably when backlogs of information are cleared. The latest confirmed data shows that almost half those known to have been infected with Ebola have died.

    Meanwhile, two children tested for Ebola after arriving in Britain from Africa are not infected, Public Health England confirmed on Saturday. It said the overall risk to the public of the virus continued to be “very low”.

    The children, whose ages and names have not been released, underwent precautionary tests in Newcastle for both the virus and malaria.

    The outbreak has been centred on Guinea, Liberia and Sierra Leone. They account for the vast majority of the cases reported to date, with about three dozen cases elsewhere.

    Liberia has recorded the highest number of cases and deaths, but the rate of infection is slowing there. The disease is now spreading fastest in Sierra Leone.

    Mali has started recording infections after sick people crossed over from neighbouring Guinea. It has reported two new cases this week.

    This outbreak has been the worst partly because it occurred in a highly mobile region, where Liberia, Guinea and Sierra Leone meet, and quickly spread to their respective capital cities.

ALNY
93.52+0.97(+1.05%)Dec 24 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Yahoo! Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Virgin America Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Noble Energy, Inc.
NYSEWed, Dec 24, 2014 2:48 PM EST